Therapy-enhancing glucan
US-9211304-B2 · Dec 15, 2015 · US
Therapy-enhancing glucan
US10307479B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10307479-B2 |
| Application number | US-201615338805-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 31, 2016 |
| Priority date | Jan 16, 2001 |
| Publication date | Jun 4, 2019 |
| Grant date | Jun 4, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of enhancing the antitumor effect of an antibody in a subject suffering from cancer, comprising administering to said subject said antibody, and a β-(1,3)-glucan obtained from oat, wheat, or moss, in an amount effective to enhance the anti-tumor effect of said antibody, wherein said glucan alone has little or no effect on said cancer, and has a molecular weight from about 40,000 to about 359,000 Daltons. 2. The method of claim 1 , wherein said antibody is a complement-activating antibody. 3. The method of claim 1 , wherein said antibody is a monoclonal antibody. 4. The method of claim 1 , wherein the cells of said cancer express CD20, HER2, EGFR, GD2 or GD3. 5. The method of claim 1 , wherein said cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma and epidermoid carcinoma.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunostimulants · CPC title
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters · CPC title
against tumor tissues, cells, antigens · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10307479B2 cover?
- This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a co…
- Who is the assignee on this patent?
- Sloan Kettering Inst Cancer Res
- What technology area does this patent fall under?
- Primary CPC classification A61K31/716. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).